144 related articles for article (PubMed ID: 32381871)
1. [Leucovorin Administration Allows Continued Pralatrexate Treatment in a Patient with Angioimmunoblastic T-Cell Lymphoma].
Sawada K; Sata H; Yasumi M; Karasuno T
Gan To Kagaku Ryoho; 2020 Jan; 47(1):95-97. PubMed ID: 32381871
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
[TBL] [Abstract][Full Text] [Related]
3. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
4. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
Shimanovsky A; Dasanu CA
Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
[TBL] [Abstract][Full Text] [Related]
5. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.
Koch E; Story SK; Geskin LJ
Leuk Lymphoma; 2013 Nov; 54(11):2448-51. PubMed ID: 23442065
[TBL] [Abstract][Full Text] [Related]
6. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.
Foss FM; Parker TL; Girardi M; Li A
Leuk Lymphoma; 2019 Dec; 60(12):2927-2930. PubMed ID: 31119966
[TBL] [Abstract][Full Text] [Related]
7. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts.
Tedeschi PM; Kathari YK; Farooqi IN; Bertino JR
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1029-32. PubMed ID: 25205429
[TBL] [Abstract][Full Text] [Related]
8. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Jennifer C Z; Sara Mohamed J; Salma A; Francine F
Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
[TBL] [Abstract][Full Text] [Related]
9. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Hosing C; Nieto YL; Oki Y
Br J Haematol; 2017 Mar; 176(5):750-758. PubMed ID: 27983760
[TBL] [Abstract][Full Text] [Related]
10. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
[TBL] [Abstract][Full Text] [Related]
11. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
Parker T; Barbarotta L; Foss F
Future Oncol; 2013 Jan; 9(1):21-9. PubMed ID: 23252560
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
Foss FM
Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
[TBL] [Abstract][Full Text] [Related]
13. Pralatrexate (Folotyn).
Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
[TBL] [Abstract][Full Text] [Related]
14. Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions.
McPherson JP; Vrontikis A; Sedillo C; Halwani AS; Gilreath JA
Pharmacotherapy; 2016 Feb; 36(2):e8-e11. PubMed ID: 26809959
[TBL] [Abstract][Full Text] [Related]
15. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.
Malik SM; Liu K; Qiang X; Sridhara R; Tang S; McGuinn WD; Verbois SL; Marathe A; Williams GM; Bullock J; Tornoe C; Lin SC; Ocheltree T; Vialpando M; Kacuba A; Justice R; Pazdur R
Clin Cancer Res; 2010 Oct; 16(20):4921-7. PubMed ID: 20739433
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.
Kelly KR; Gabrail N; Weitman S; Sarantopoulos J; Olszanski AJ; Edenfield W; Venitz J; Reddy G; Yang A; Hasal SJ; Lockhart AC
Cancer Chemother Pharmacol; 2016 Nov; 78(5):929-939. PubMed ID: 27638045
[TBL] [Abstract][Full Text] [Related]
17. Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate.
Sekiguchi Y; Wakabayashi M; Takizawa H; Iizuka H; Sakajiri S; Sugimoto K; Inano T; Fukuda Y; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Komatsu N; Noguchi M
J Clin Exp Hematop; 2020; 60(1):26-28. PubMed ID: 32224563
[No Abstract] [Full Text] [Related]
18. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
Duvic M; Kim YH; Zinzani PL; Horwitz SM
Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
[No Abstract] [Full Text] [Related]
19. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
Azzoli CG; Patel JD; Krug LM; Miller V; James L; Kris MG; Ginsberg M; Subzwari S; Tyson L; Dunne M; May J; Huntington M; Saunders M; Sirotnak FM
J Thorac Oncol; 2011 Nov; 6(11):1915-22. PubMed ID: 21841501
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis.
Zhu J; Yeoh EM; Maeda Y; Tobinai K
Leuk Lymphoma; 2020 Sep; 61(9):2145-2152. PubMed ID: 32536233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
